Moreover, our study highlights the clinical relevance of these findings, demonstrating the increased expression of SHH, p‐STAT3, and GLI1 proteins in postosimertinib‐resistant lung cancer tissues, along with decreased DUSP13B expression. This evidence concerns the gene DUSP13B and lung cancer.